Literature DB >> 1453524

Epidemiology of invasive pneumococcal infections in children in Finland.

J Eskola1, A K Takala, E Kela, E Pekkanen, R Kalliokoski, M Leinonen.   

Abstract

OBJECTIVE: To study the epidemiologic characteristics of invasive infections in children caused by Streptococcus pneumoniae to provide background data for vaccination programs.
DESIGN: A nationwide laboratory-based prospective surveillance of all invasive pneumococcal infections in children during 1985 through 1989.
SETTING: A network of all microbiologic laboratories and pediatric wards in Finland. PATIENTS: Children aged 0 to 15 years who were admitted to a hospital with S pneumoniae isolated from blood, cerebrospinal fluid, or deep aspirate sample.
RESULTS: Four hundred fifty-two invasive pneumococcal infections were diagnosed in 1985 through 1989. The annual incidence rate was 8.9 per 100,000 children less than 16 years of age (24.2 per 100,000 among children less than 5 years of age and 45.3 per 100,000 among those less than 2 years of age). The most common clinical entities were bacteremia without focus (310 cases), pneumonia (66 cases), and meningitis (51 cases), with other focal infections seen in 25 cases. The pneumococcal groups/types 14, 6, 19, 7, 18, and 23 comprised 78% of all invasive infections.
CONCLUSIONS: Streptococcus pneumoniae is a common cause of invasive infections in children in Finland. A pneumococcal conjugate vaccine containing the six most common groups/types could prevent up to 70% of invasive pneumococcal infections of children in Finland if fully protective in infancy.

Entities:  

Mesh:

Year:  1992        PMID: 1453524

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  34 in total

Review 1.  New pneumococcal vaccines for children.

Authors:  S Choo; A Finn
Journal:  Arch Dis Child       Date:  2001-04       Impact factor: 3.791

Review 2.  Vaccines for tomorrow.

Authors:  S K Sood
Journal:  Indian J Pediatr       Date:  1995 May-Jun       Impact factor: 1.967

3.  Interleukin-1β regulates CXCL8 release and influences disease outcome in response to Streptococcus pneumoniae, defining intercellular cooperation between pulmonary epithelial cells and macrophages.

Authors:  Helen M Marriott; Kate A Gascoyne; Ravi Gowda; Ian Geary; Martin J H Nicklin; Francesco Iannelli; Gianni Pozzi; Timothy J Mitchell; Moira K B Whyte; Ian Sabroe; David H Dockrell
Journal:  Infect Immun       Date:  2011-12-12       Impact factor: 3.441

4.  Influence of patient age on Streptococcus pneumoniae serotypes causing invasive disease.

Authors:  J Inostroza; A M Vinet; G Retamal; P Lorca; G Ossa; R R Facklam; R U Sorensen
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

5.  Assignment of immunoglobulin G1 and G2 concentrations to pneumococcal capsular polysaccharides 3, 6B, 14, 19F, and 23F in pneumococcal reference serum 89-SF.

Authors:  A Soininen; I Seppälä; T Wuorimaa; H Käyhty
Journal:  Clin Diagn Lab Immunol       Date:  1998-07

6.  Persistent Sex Disparities in Invasive Pneumococcal Diseases in the Conjugate Vaccine Era.

Authors:  Annabelle de St Maurice; William Schaffner; Marie R Griffin; Natasha Halasa; Carlos G Grijalva
Journal:  J Infect Dis       Date:  2016-05-30       Impact factor: 5.226

7.  Pneumolysin PCR-based diagnosis of invasive pneumococcal infection in children.

Authors:  P Toikka; S Nikkari; O Ruuskanen; M Leinonen; J Mertsola
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

8.  Prevention of Pneumococcal Meningitis.

Authors:  Tina Q. Tan
Journal:  Curr Infect Dis Rep       Date:  2002-08       Impact factor: 3.725

9.  Immunoglobulin G antibody responses to polyvalent pneumococcal vaccine in children in the highlands of Papua New Guinea.

Authors:  W S Pomat; D Lehmann; R C Sanders; D J Lewis; J Wilson; S Rogers; T Dyke; M P Alpers
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

10.  Seasonal patterns of invasive pneumococcal disease.

Authors:  Scott F Dowell; Cynthia G Whitney; Carolyn Wright; Charles E Rose; Anne Schuchat
Journal:  Emerg Infect Dis       Date:  2003-05       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.